Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (ACET)
NASDAQ:ACET
Adicet Bio (ACET) Stock Price & Analysis
545 Followers
ACET Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.10 - $6.65
Previous Close$1.6
Volume1.06M
Average Volume (3M)1.42M
Market Cap
$131.48M
Enterprise Value-$7.31M
Total Cash (Recent Filing)$159.71M
Total Debt (Recent Filing)$20.92M
Price to Earnings (P/E)-0.5
Beta1.25
Next Earnings
Aug 07, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.95
Shares Outstanding82,173,503
10 Day Avg. Volume1,376,058
30 Day Avg. Volume1,424,596
Standard Deviation0.28
R-Squared0.13
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.50
Price to Sales (P/S)184.14
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.24
Enterprise Value/Gross Profit-10.24
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$9.20Price Target Upside475.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Shares Insights at Gene and Cell Therapy Meeting
PremiumCompany Announcements
Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
PremiumPre-Earnings
Is ACET a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsAdicet's differentiated approach to target CD70 in solid tumors sets it apart from its peers, promising a unique position in oncology treatments.
Financial StabilityAdicet's significant net proceeds from public offerings and at-the-market programs have fortified its financial position, with a cash runway extending into the second half of 2026.
Regulatory MilestonesThe FDA's approval of Adicet's IND for lupus nephritis paves the way for clinical trials, showcasing the company's regulatory progress and potential for future growth.
Bears Say
Clinical TrialsThere are concerns about the lack of long-term anti-tumor effects, as indicated by tumor regrowth in rechallenged mice.
Financial PerformanceAdicet reported a loss per share for the year, indicating financial challenges ahead for the company.
Market CompetitionAdicet's peers in the CD70 space have shown varied results, with some inconclusive outcomes, indicating a competitive and uncertain market.
---
Ownership Overview
26.27% Insiders
4.30% Mutual Funds
55.73% Other Institutional Investors
13.70% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACET FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest stock price was $1.10 and its highest was $6.65 in the past 12 months.
What is Adicet Bio’s market cap?
Currently, no data Available
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is Aug 07, 2024 which is in 80 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on May 14, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.448 by $0.098.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -$0.38.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,173,500 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.448. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Adicet Bio?
Among the largest hedge funds holding Adicet Bio’s share is Wexford Capital LP. It holds Adicet Bio’s shares valued at 28K.
---
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (475.00% Upside)
$9.20 (475.00% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 14.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.01%
12-Months-Change
Fundamentals
Return on Equity
-53.25%
Trailing 12-Months
Asset Growth
-3.90%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
ACET Stock 12 Month Forecast
Average Price Target
$9.20
▲(475.00% Upside)
Technical Analysis
Best Analysts Covering ACET
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-1.27%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -1.27% per trade.
---